Wutah dodolan triwulanan: Natera Medical (NTRA)

Simbol lan logo merek Natera, Inc. (NTRA)

The explosive adoption of non-invasive genetics is driving the expansion of Natera, Inc. (NTRA), as confirmed by the current quarterly revenue chart from the GURU.Markets platform, where the current status is 34.40. Growth is based on the scalability of DNA algorithms that reduce costs as test volumes increase. Stability is ensured by steady demand for cancer screening, despite dependence on insurance reimbursements and R&D expenditures.

NTRA (Natera Corp) riwayat Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 20.11.2026

Ringkesan rincian data analitis Natera Corp (NTRA)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
- data dhuwit lan arus kas:
Analisis umum perusahaan:natera.com (NTRA)
Produk sing diprodhuksi Natera Inc

Quarterly revenue growth reflects the rate of change in Natera, Inc. (NTRA) operating income compared to the same period last year. By analyzing the quarterly percentage growth in revenue, an investor assesses the dynamics of actual market transactions excluding accounting adjustments. This metric is sensitive to seasonality and the volume of new contracts, determining the fundamental resilience of the business. For Natera, Inc. (NTRA), this indicator depends directly on the scaling of DNA test sales in oncology and prenatal screening.